SAN DIEGO, May 12, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces the award of a patent by the U.S. Patent and Trademark Office covering the use of a novel stain in the detection of rare cells such as circulating tumor cells (CTCs) from blood and other biological fluids. U.S. Patent 9,347,946 entitled METHODS AND REAGENTS FOR SIGNAL AMPLIFICATION will publish on May 24, 2016.
"With the issuance of this patent, we have now completed our patent portfolio to include all key components central to our Cell Enrichment and Extraction (CEE™) platform for the transport, capture, enrichment, identification and analysis of CTCs from blood samples and other biological fluids," said Lyle Arnold, Ph.D., Biocept's Senior Vice President and Chief Scientific Officer. "We have corresponding patents either granted or pending on a worldwide basis."
The newly issued patent covers a staining method employed in the CEE platform that provides for the high-efficiency capture, visualization and microscopic analysis of targeted cells that are obtained from biofluid samples. This patent interfaces well with Biocept's previously granted patents using antibody cocktails to bind to and capture CTCs, and completes the coverage of Biocept's core CTC platform. The components of the platform are as follows: 1) A unique preservative in a proprietary collection tube used for analyzing cancer materials from fluids including blood; 2) antibody cocktails used for rare cell capture in biofluids; 3) microchannels for rare cell enrichment and analysis including CTCs; and 4) a unique cell-staining method used to identify targets captured in the microchannel, which is the subject of this patent.
"We have been aggressively broadening our IP protection for our unique methods of capturing and analyzing cancer cells in blood and other biological fluids," said Biocept's President and CEO Michael Nall. "Our expanding portfolio of U.S. and international patents better positions Biocept to capitalize on the growing movement toward the use of liquid biopsy, which can reduce healthcare system costs and, importantly, help physician in treatment decision-making for their patients with cancer."
Biocept, Inc. is a molecular diagnostics company with commercial tests targeting lung, breast, gastric, colorectal and prostate cancers and melanoma. The company uses its proprietary liquid biopsy technology to provide physicians with more precise information for treating and monitoring patients with cancer. The company's patented Target Selector™ liquid biopsy technology platform captures and analyzes circulating material in both CTCs and in plasma (ctDNA). After thousands of tests, the platform has proven to be effective in identifying cancer mutations. For additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the detection and treatment of cancer, our ability to capitalize on the growing movement toward the use of liquid biopsy, and our impact on diagnostic strategies and healthcare costs, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biocept-expands-intellectual-property-portfolio-with-12th-granted-patent-on-its-key-liquid-biopsy-technology-300267123.html
SOURCE Biocept, Inc.